证券代码：300354 证券简称：东华测试 公告编号：2023-042 江苏东华测试技术股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏东华测试技术股份有限公司（以下简称"公司"）于2023年8月7日通过 电子邮件、直接送达等方式向全体董事发出第五届董事会第十五次会议的会议通 知及相关资料。本次会议于2023年8月18日在公司会议室以现场结合通讯方式召 开。 本次会议由董事长刘士钢召集和主持，应出席董事7名，实际出席董事7名， 公司监事和有关高级管理人员列席了会议。会议的召集及召开程序符合《中华人 民共和国公司法》及《公司章程》的规定。 二、董事会会议审议情况 与会董事就会议议案进行了审议、表决，形成了如下决议： 1、审议通过《关于公司 2023 年半年度报告全文及摘要的议案》 全体董事一致认为《公司 2023 年半年度报告全文及摘要》的编制程序、半 年报内容、格式符合相关文件的规定；编制期间，未有泄密及其他违反法律法规、 《公司章程》或损害公司利益的行为发生；公司的财务报告真实、准确 ...

证券代码：300354 证券简称：东华测试 公告编号：2023-043 江苏东华测试技术股份有限公司 第五届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 江苏东华测试技术股份有限公司（以下简称"公司"）于 2023 年 8 月 7 日 通过电子邮件、直接送达等方式向全体监事发出第五届监事会第十四次会议的会 议通知及相关资料。本次会议于 2023 年 8 月 18 日在公司会议室以现场会议的方 式召开。 本次会议由监事会主席孙丽丽召集和主持，应出席监事 5 名，实际出席监 事 5 名。会议的召集及召开程序符合《中华人民共和国公司法》及《公司章程》 的规定。 二、监事会会议审议情况 与会监事经过认真讨论，审议并通过了以下决议： 1、审议通过《关于公司 2023 年半年度报告全文及摘要的议案》 经审核，监事会认为：公司《2023 年半年度报告》的编制程序、内容、格式 符合相关文件的规定；半年报编制期间，未有泄密及其他违反法律法规、《公司 章程》或损害公司利益的行为发生；公司的财务报告真实、准确、完整地反映了 公司 ...

编制单位：江苏东华测试技术股份有限公司 单位：元 | | 资金占用方 | 占用方与上市公 | 上市公司核算 | 2023 年期初 | 2023 | 年半年度占 | 2023 年半年度占 | 2023 | 年半年 | 2023 年半年 | 占用形 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 名称 | 司的关联关系 | 的会计科目 | 占用资金余额 | 用累计发生金额 | | 用资金的利息 | 度偿还累计 | | 度期末占用 | 成原因 | 占用性质 | | | | | | | （不含利息） | | （如有） | 发生金额 | | 资金余额 | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | | | 小计 | - | - | - | | | | | | | | | - | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | | | | | 小计 | - | - | - | | | | | | ...

Financial Performance - The company's revenue for Q1 2023 was CNY 71,868,895.80, representing a 54.52% increase compared to CNY 46,512,531.55 in the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was CNY 10,288,726.35, a significant increase of 116.20% from CNY 4,759,001.46 in the previous year[5] - The basic earnings per share for Q1 2023 was CNY 0.0744, up 116.28% from CNY 0.0344 in the same period last year[5] - Total operating revenue for Q1 2023 reached ¥71,868,895.80, a significant increase of 54.5% compared to ¥46,512,531.55 in the same period last year[24] - The net profit for Q1 2023 was CNY 10,288,726.35, a significant increase of 116.5% compared to CNY 4,759,001.46 in Q1 2022[26] - Operating profit reached CNY 12,028,586.77, up from CNY 5,762,492.12, reflecting a growth of 108.8% year-over-year[26] - Total comprehensive income for the period was CNY 10,288,726.35, which is a 116.5% increase from CNY 4,759,001.46 in the same period last year[26] - Basic and diluted earnings per share were both CNY 0.0744, up from CNY 0.0344, representing a growth of 116.5%[26] Assets and Liabilities - The company's total assets at the end of Q1 2023 were CNY 680,933,361.22, a decrease of 1.64% from CNY 692,310,717.17 at the end of the previous year[5] - Current assets totaled ¥522,636,804.16, down 4.4% from ¥546,998,355.01 at the start of the year[22] - Cash and cash equivalents decreased significantly to ¥62,267,776.25 from ¥121,364,777.42, a drop of 48.7%[22] - Total liabilities decreased to ¥68,259,215.92 from ¥92,521,773.22, a reduction of 26.2%[22] - The company's equity attributable to shareholders rose to ¥612,674,145.30, an increase of 2.9% from ¥599,788,943.95[23] Cash Flow - Cash flow from operating activities for Q1 2023 was negative at CNY -19,010,862.64, worsening by 25.53% compared to CNY -15,144,590.79 in the same period last year[5] - Cash inflow from operating activities totaled CNY 92,204,474.63, compared to CNY 47,190,039.46 in the previous year, indicating a growth of 95.5%[28] - The net cash flow from operating activities was negative at CNY -19,010,862.64, worsening from CNY -15,144,590.79 in Q1 2022[28] - The company experienced a cash decrease of CNY 58,612,775.79 during the quarter, compared to a decrease of CNY 15,835,657.79 in Q1 2022[29] Investments and Expenses - Research and development expenses increased by 48.23% to CNY 10,129,747.16 in Q1 2023, reflecting the company's commitment to innovation[12] - The cash paid for purchasing fixed assets and other long-term assets in Q1 2023 was CNY 19,601,913.15, a dramatic increase of 2736.47% compared to CNY 691,067.00 in the same period last year[14] - Total operating costs for Q1 2023 were ¥59,898,301.52, up 41.3% from ¥42,394,056.81 in Q1 2022[24] - The total cash outflow from investing activities was CNY 39,601,913.15, compared to CNY 691,067.00 in the previous year, indicating a significant increase in investment activities[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 4,778[16] - Liu Shigang holds 48.99% of shares, totaling 67,765,930 shares, with 50,824,447 shares under lock-up[16] - The top 10 shareholders include Liu Shigang, Luo Mian, and several investment funds, with the largest being Liu Shigang[16] - Sun Huiming holds 3.47% of shares, totaling 4,806,000 shares, with 3,606,000 shares held through margin trading[17] - The total number of restricted shares at the beginning of the period was 58,410,782, with 57,663 shares released during the period[19] - The company has a total of 50,824,447 shares under lock-up for Liu Shigang, which is calculated based on 25% of the total shares held at the end of the previous year[19] - Luo Mian has 6,414,825 shares under lock-up, also calculated based on the same method[19] - The company is currently unaware of any other shareholders having related party relationships or being considered as acting in concert[17] Other Information - The company has no new important matters to report for the quarter[20] - The report indicates that there are no changes in the number of preferred shareholders[18] - The company has not undergone an audit for the Q1 2023 report[30]

1 / 2 | | 售副总"销售团队体系。电化学工作站销售团队 30 余人，业 | | --- | --- | | | 务独立。基于 的设备智能维保管理平台主要采用代理商 PHM | | | 销售模式，目前代理商有 16 个。 | | | 2、去年年底教育贴息对行业的影响？ | | | 答：公司认为教育贴息对仪器仪表行业有一定的积极促进作 | | | 用，叠加宏观国产替代趋势，将更多利好掌握核心技术的中 | | | 高端国产化仪器厂家。 | | | 3、新技术如何和公司产品相融合？ | | | 答：公司追求技术升级，公司最大的技术优势是感知系统， | | | 可靠性高，抗干扰能力强，稳定性高。 | | | 4、公司近几年毛利率净利率上升较快，未来的趋势是怎样 | | | 的？ | | | 答：公司以健康运营为目标，未来毛利率净利率不会有太大 | | | 变化。 | | | 5、公司费用端下降较快的原因。 | | | 答：一般而言，多品种小批量生产的费用会比较高，但公司 | | | 不断提升模块化程度、自动化程度，进一步提高定制效率， | | | 从而降低了费用。 | | | 6、请介绍一下公司产能规划情况。 ...

Financial Performance - The company's operating revenue for 2022 was ¥367,082,438.42, representing a 42.81% increase compared to ¥257,042,601.70 in 2021[18]. - The net profit attributable to shareholders for 2022 was ¥121,774,983.07, a 52.17% increase from ¥80,023,924.21 in 2021[18]. - The net profit after deducting non-recurring gains and losses was ¥117,372,893.18, up 52.36% from ¥77,039,059.03 in the previous year[18]. - The basic earnings per share for 2022 was ¥0.88, reflecting a 51.72% increase from ¥0.58 in 2021[18]. - The total assets at the end of 2022 amounted to ¥692,310,717.17, a 26.96% increase from ¥545,294,354.68 at the end of 2021[18]. - The net assets attributable to shareholders increased by 21.25% to ¥599,788,943.95 at the end of 2022, compared to ¥494,682,998.00 at the end of 2021[18]. - The company reported a net cash flow from operating activities of ¥31,377,544.40, which is a 14.18% increase from ¥27,481,524.61 in 2021[18]. - The weighted average return on equity for 2022 was 22.17%, up from 17.43% in 2021, indicating improved profitability[18]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of ¥1.77 per 10 shares to all shareholders, based on a total of 138,320,201 shares[4]. - The cash dividend distribution plan for 2021 was approved, with a cash dividend of 1.75 yuan per 10 shares, totaling 24,482,675.58 yuan[129]. - The total distributable profit for the parent company as of December 31, 2022, is 296,648,991.01 yuan, with a net profit of 106,673,804.92 yuan for the year[129]. Research and Development - The company has developed 19 authorized patents and 45 software copyrights, showcasing its strong R&D capabilities[44]. - The company has implemented a flexible and agile production model to enhance product quality and meet customer demands[40]. - The company is focusing on the development of new products, including the DH5960N rugged high-speed data acquisition system and the DH5981A dual 24-bit AD portable dynamic signal testing and analysis system, among others[96]. - The number of R&D personnel increased to 241 in 2022, up 30.98% from 184 in 2021, with R&D personnel now accounting for 37.31% of the total workforce[69]. - R&D investment amounted to ¥34,621,047.69 in 2022, representing 9.43% of total revenue, a decrease from 10.54% in 2021[69]. Market and Product Development - The company specializes in structural mechanics performance testing and has been focused on intelligent measurement and control systems for nearly 30 years[28]. - The demand for structural mechanics performance testing systems is increasing due to the digital transformation and the need for structural safety in various industries[29]. - The company aims to leverage emerging technologies such as big data and AI to enhance its product offerings and market competitiveness[30]. - The overall market for high-end scientific instruments is expected to expand, driven by national policies supporting R&D investment[29]. - The company has developed a predictive maintenance management platform that integrates health prediction models with IT technology, enhancing equipment management[35]. Operational Efficiency - The company has established a procurement management system to ensure product quality through strict acceptance and inventory procedures[39]. - The company has implemented measures to protect its core technologies, including applying for patents and establishing confidentiality agreements with employees[98]. - The company is addressing rising costs by improving product standardization and quality control, as well as expanding production volumes to reduce unit costs[98]. - The company has established a calibration and testing subsidiary to ensure the accuracy of its instruments throughout their lifecycle[48]. Risk Management - The company has outlined potential risks and countermeasures in its management discussion and analysis section, emphasizing the importance of risk awareness for investors[4]. - The company faces risks related to new product development, including potential delays in market promotion and competition from domestic and international peers[96]. - The company is actively responding to external risks by optimizing organizational structures and enhancing core competitiveness through staff training[97]. Corporate Governance - The company has a supervisory board consisting of 5 members, including 2 employee supervisors, complying with legal and regulatory requirements[102]. - The performance evaluation and incentive mechanism links employee income to work performance, aligning with the company's development status[102]. - The company has established a management system for information disclosure to ensure the accuracy and timeliness of information provided to shareholders[102]. - The governance situation of the company aligns with the requirements of the Company Law and the regulations set by the China Securities Regulatory Commission[103]. Social Responsibility and Sustainability - The company donated 200,000 yuan to the Yangzhou University Education Development Foundation to establish the "Donghua Testing Scholarship Fund" during the reporting period[142]. - The company has implemented an environmental management system and received certification in May 2021, demonstrating its commitment to green and low-carbon development[142]. - The company actively engages in social responsibility initiatives, emphasizing the integration of corporate and social benefits[142]. Financial Management - The company has completed all fundraising projects from its initial public offering, with total raised funds of CNY 195.07 million fully utilized by the end of the reporting period[80]. - The company has a remaining balance of 2,578.4 million in raised funds, which will be used for working capital[83]. - The company has effectively managed cash from idle fundraising, generating some financial returns during the holding period[85]. - The company reported a standard unqualified audit opinion for the financial statements as of December 31, 2022, indicating fair representation of its financial condition and results[195].

二、会议召开时间和地点 召开时间：2023年3月24日（星期五）下午15:30--17:00 召开方式：现场 证券代码：300354 证券简称：东华测试 公告编号：2023-018 江苏东华测试技术股份有限公司 关于举行2022年度业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏东华测试技术股份有限公司（以下简称"公司"）2022年年度报告于2023年3月 10日在巨潮资讯网（www.cninfo.com.cn）披露，为了让广大投资者进一步了解公司的经 营业绩、财务状况等情况，加强公司与投资者的沟通互动，公司拟于2023年3月24日（星 期五）下午15:30--17:00召开2022年度业绩说明会。 一、会议类型 本次业绩说明会以现场会议方式召开，公司将针对2022年度的经营成果及财务指标 的具体情况与投资者进行互动交流和沟通，欢迎广大投资者积极参与。 1 五、联系人及联系方式 召开地点：江苏省靖江市新港大道208号（沿江公路罗家港桥东北侧） 三、参会人员 公司董事长、总经理、独立董事、董事会秘书、财务总监及相关部门人员。 四、投资者参加 ...

证券代码：300354 证券简称：东华测试 江苏东华测试技术股份有限公司投资者关系活动记录表 编号：2015-12-30 | --- | --- | --- | |-------------|-------------------------------|--------------------------------------------------------------| | | | | | 投 资 者 关 | □ 特定对象调研 | □ 分析师会议 | | 系 活 动 类 | R 媒体采访 | □ 业绩说明会 | | 别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参 与 单 位 | 证券时报 记者 张旭升 | | | 名 称 及 人 | 中国基金报 记者 张琳梓 | | | 员姓名 | 益正金融 研究员 赵安 | | | 时间 | 2015 年 12 月 30 日 | 10:00-11:30 | | 地点 | 江苏东华测试技术股份有限公司 | A301 | | 上 市 公 司 | | | | 接 待 人 员 | 董事长刘士钢 | 董秘瞿小松 ...